NCT03474822View on ClinicalTrials.gov

Plasmodium Immunotherapy for Breast and Liver Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 10, 2018

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2026

Conditions
Advanced Breast CancerAdvanced Liver Cancer
Interventions
BIOLOGICAL

Blood-stage infection of P.vivax

The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.

Trial Locations (1)

510000

RECRUITING

Plasmodiun vivax, Guangzhou

All Listed Sponsors
lead

CAS Lamvac Biotech Co., Ltd.

INDUSTRY